Painless lymphocytic thyroiditis

Because of the increased risk of permanent hypothyroidism developing over time, patients who have had painless thyroiditis and recovered normal thyroid function should be monitored with periodic thyroid-stimulating hormone measurements. There are no data to support specific recommendations for monitoring intervals. However, patients with higher titres of thyroid peroxidase (TPO) antibodies develop permanent hypothyroidism more rapidly than those with low or absent titres. Continued monitoring at least every 5 years for patients with persistent high titre TPO antibodies is advised for sporadic painless thyroiditis. It is recommended to test thyroid function every 3 months for 4 years after the last alemtuzumab dose.[8]Muller I, Moran C, Lecumberri B, et al. 2019 European Thyroid Association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. Eur Thyroid J. 2019 Jul;8(4):173-85. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738237 http://www.ncbi.nlm.nih.gov/pubmed/31602359?tool=bestpractice.com ​​